Immunohistochemical (IHC) results in a validation set of 84 FLs, including 42 t(14;18)-positive and 42 t(14;18)-negative FL
Antibodies (IHC) . | t(14;18)+ . | t(14;18)− . | P . |
---|---|---|---|
CD10 | < .01 | ||
Negative | 0/42 (0) | 12/38 (31.6) | |
Positive | 42/42 (100) | 26/38 (68.4) | |
BCL6 | — | ||
Positive | 40/40 (100) | 38/38 (100) | |
IRF4/MUM1 | .039 | ||
No greater than 10% | 42/42 (100) | 31/35 (88.6) | |
Greater than 10% | 0/0 (0) | 4/35 (11.4) | |
IRF8 | NS | ||
Negative | 3/39 (7.7) | 1/38 (2.6) | |
Positive | 36/39 (92.3) | 37/38 (97.4) | |
Ki67 | < .01 | ||
No greater than 25% | 17/41 (41.5) | 3/33 (9.1) | |
Greater than 25% | 24/41 (58.5) | 30/33 (90.9) | |
GRZMB | < .01 | ||
No greater than 3% | 29/36 (80.6) | 16/35 (45.7) | |
Greater than 3% | 7/36 (19.4) | 19/35 (54.3) | |
FOXP3 | NS | ||
No greater than 5% | 19/40 (47.5) | 11/36 (30.55) | |
Greater than 5% | 21/40 (52.5) | 25/36 (69.4) | |
CD57 | NS | ||
No greater than 15% | 33/40 (82.5) | 35/37 (94.6) | |
Greater than 15% | 7/40 (17.5) | 2/37 (5.4) |
Antibodies (IHC) . | t(14;18)+ . | t(14;18)− . | P . |
---|---|---|---|
CD10 | < .01 | ||
Negative | 0/42 (0) | 12/38 (31.6) | |
Positive | 42/42 (100) | 26/38 (68.4) | |
BCL6 | — | ||
Positive | 40/40 (100) | 38/38 (100) | |
IRF4/MUM1 | .039 | ||
No greater than 10% | 42/42 (100) | 31/35 (88.6) | |
Greater than 10% | 0/0 (0) | 4/35 (11.4) | |
IRF8 | NS | ||
Negative | 3/39 (7.7) | 1/38 (2.6) | |
Positive | 36/39 (92.3) | 37/38 (97.4) | |
Ki67 | < .01 | ||
No greater than 25% | 17/41 (41.5) | 3/33 (9.1) | |
Greater than 25% | 24/41 (58.5) | 30/33 (90.9) | |
GRZMB | < .01 | ||
No greater than 3% | 29/36 (80.6) | 16/35 (45.7) | |
Greater than 3% | 7/36 (19.4) | 19/35 (54.3) | |
FOXP3 | NS | ||
No greater than 5% | 19/40 (47.5) | 11/36 (30.55) | |
Greater than 5% | 21/40 (52.5) | 25/36 (69.4) | |
CD57 | NS | ||
No greater than 15% | 33/40 (82.5) | 35/37 (94.6) | |
Greater than 15% | 7/40 (17.5) | 2/37 (5.4) |
Values are n (%).
NS indicates not significant.